Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc. (AGN.CN) Financial Performance & Income Statement Overview
Review Algernon Pharmaceuticals Inc. (AGN.CN) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Algernon Pharmaceuticals Inc. (AGN.CN) Income Statement & Financial Overview
Explore comprehensive income reports for Algernon Pharmaceuticals Inc. AGN.CN, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $5984.00 | $0.00 | $0.00 | $6085.00 |
| Gross Profit | -$5984.00 | $0.00 | $0.00 | -$6085.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $4169.00 | $32800.00 | $35033.00 | $109534.00 |
| SG&A Expenses | $362374.00 | $348523.00 | $385167.00 | $356124.00 |
| Operating Expenses | $366543.00 | $381323.00 | $420200.00 | $465658.00 |
| Total Costs & Expenses | -$372527.00 | $381323.00 | $420200.00 | $465659.00 |
| Interest Income | $260.00 | $260.00 | $260.00 | $380.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $5984.00 | $5560.00 | $5407.00 | $6085.00 |
| EBITDA | -$366283.00 | -$375763.00 | -$414793.00 | -$436212.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$372527.00 | -$381583.00 | $0.00 | -$465660.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $260.00 | $520.00 | -$421434.00 | $1.91M |
| Income Before Tax | -$372267.00 | -$381063.00 | -$421434.00 | $1.44M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$372267.00 | -$381063.00 | -$421434.00 | $1.44M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.01 | -$0.01 | -$0.02 | $0.07 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.02 | $0.06 |
| Weighted Avg Shares Outstanding | $27.30M | $27.30M | $21.78M | $21.78M |
| Weighted Avg Shares Outstanding (Diluted) | $27.30M | $27.30M | $23.67M | $22.28M |
Over the last four quarters, Algernon Pharmaceuticals Inc. achieved steady financial progress, growing revenue from $0.00 in Q3 2024 to $0.00 in Q2 2025. Gross profit stayed firm with margins at N/A in Q2 2025 versus N/A in Q3 2024. Operating income totaled -$372527.00 in Q2 2025, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$366283.00. Net income rose to -$372267.00, with EPS at -$0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan